Impact of hematocrit on morbidity and mortality

Seminars in Nephrology

Volumn 20, Issue 4, 2000, Pages 345-349

  Collins, Allan J ^a,b   Ma, Jennie Z ^a   Ebben, James ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; HEMATOCRIT; HEMODIALYSIS; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATOCRIT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MORBIDITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 0033928508     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/SNEP.2000.6466     Document Type: Article

References (25)

1. Health Care Financing Administration: Medicare Program; Coverage of Epoetin Alfa (rHuEPO) Used by Competent Home Dialysis Patients. 42 CFR Parts 405,410, 413, and 414. 1-10-1994. BPD-737-F; RIN 0938-AF54. Ref Type: Bill/Resolution
2. Muirhead N, Hodsman AB: Occult infection and resis-tance of anaemia to epoetin (rHuEPO) therapy in renal failure. Nephrol Dial Transplant 5:232-234, 1990
3. Almond MK, Tailor D, Marsh RP, et al: Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant 9:270-273, 1994
4. Drueke TB: Erythropoietin hyporesponsiveness - Who and why? Nephrol Dial Transplant 10:62-68, 1995
5. Douglas SW, Adamson JW: The anemia of chronic disorders: Studies of marrow regulation and iron metabolism. Blood 45:55-65, 1975
6. Hymes LC, Hawthorne SM, Clowers BM: Impaired response to recombinant erythropoietin therapy in children with peritonitis. Dial Transplant 23:462-463, 1994
7. Danielson B: Erythropoietin hyporesponsiveness - Who and why? Nephrol Dial Transplant 10:69-73, 1995
8. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
9. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171-175, 1993
10. Tomson CR, Edmunds ME, Chambers K, et al: Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 7:817-821, 1992
11. Cheng IKP, Lu H, Wei DCC, et al: Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 13:142-148, 1993
12. Lai KN, Wong KC, Li PKT, et al: Use of recombinant erythropoietin in thalassemic patients on dialysis. Am J Kidney Dis 19:239-245, 1992
13. Madore F, Bridges K, Brugnara NL, et al: A population study of the interplay between iron, nutrition, and inflammation in erythropoiesis in hemodialysis patients. J Am Soc Nephrol 7:1456, 1996 (abstr)
14. Sumes MA, Ronnholm KAR, Antikainen M, et al: Fac-tors limiting the erythropoietin response in rapidly growing infants with congenital nephrosis on a peritoneal dialysis regimen after nephrectomy. J Pediatr 120:44-48, 1992
15. Eknoyan G, Levin N: Clinical Practice Guidelines: Final Guideline Summaries from the Work Groups of the National Kidney Foundation - Dialysis Outcomes Quality Initiative. New York, National Kidney Foundation, 1997
16. Madore F, Lowrie E, Brugnara C, et al: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8:1921-1929, 1997
17. Owen W, Lew N, Liu Y, et al: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Eng J Med 329:1001-1006, 1993
18. Ma J, Ebben J, Xia H, et al: Hct level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
19. Collins AJ, Ebben J, Ma J: Clinical factors associated with changing Hct levels in hemodialysis patients. Semin Dialysis 12:S-92-S-96, 1999 (suppl 1)
20. Collins A, Xia H, Ebben J, et al: Change in Hct and risk of mortality. J Am Soc Nephrol 9:204A, 1998 (abstr)
21. Collins A, Xia H, Ebben J, et al: Change in Hct and risk of hospitalizations. J Am Soc Nephrol 9:204A, 1998 (abstr)
22. Churchill DN, Muirhead N, Goldstein M, et al: Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 43:184-188, 1995
23. Xia H, Ebben J, Ma J, et al: Hct levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316, 1999
24. Pickett JL, Theberge DC, Brown WS, et al: Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33:1122-1130, 1999
25. Besarab A, Bolton JK, Browne JK, et al: The effects of normal as compared with low Hct values in patients with cardiac disease who are receiving hemodialysis and epoetin therapy. N Eng J Med 339:584-590, 1998